27 October 2025
27 October 2025
The acquisition will integrate Avidity’s late-stage neuroscience assets into Novartis.
For Adverum, the potential buyout from Eli Lilly provides financial respite.
Dupixent’s Q3 sales increased by 26.2%, breaking through the €4bn ceiling for the first time in a single quarter.
The raid follows an uptick in the trade of illegal GLP-1RA drugs used for obesity and type 2 diabetes.
The new biotech prepares to initiate Phase I testing, setting its sights on “total allergic control”.
Lilly and Inctye will be seeking a label update for the JAK inhibitor for its use in paediatric patients.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
